Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been given a $75.00 price objective by investment analysts at Piper Jaffray Companies in a report issued on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price would suggest a potential upside of 52.59% from the stock’s previous close.

Several other research firms also recently weighed in on EGRX. BidaskClub downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 30th. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 16th. Royal Bank Of Canada raised their target price on Eagle Pharmaceuticals from $86.00 to $94.00 and gave the company an “outperform” rating in a research report on Tuesday, May 9th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, Mizuho decreased their target price on Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating on the stock in a research report on Thursday, May 25th. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Eagle Pharmaceuticals has an average rating of “Hold” and an average target price of $75.40.

Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 49.15 on Wednesday. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15. The stock’s 50 day moving average price is $69.01 and its 200-day moving average price is $76.30. The stock has a market capitalization of $751.90 million, a PE ratio of 7.72 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.44 by $0.02. The business had revenue of $76.80 million for the quarter, compared to analysts’ expectations of $70.10 million. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The business’s revenue for the quarter was up 159.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS. On average, equities analysts expect that Eagle Pharmaceuticals will post $3.38 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Analysts Give Eagle Pharmaceuticals, Inc. (EGRX) a $75.00 Price Target” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/10/piper-jaffray-companies-analysts-give-eagle-pharmaceuticals-inc-egrx-a-75-00-price-target.html.

In related news, CFO Pete A. Meyers acquired 350 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The shares were purchased at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now owns 350 shares in the company, valued at approximately $25,021.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have purchased 805 shares of company stock worth $61,790. 19.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue increased its position in shares of Eagle Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock worth $125,000 after buying an additional 702 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 202 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 120 shares during the last quarter. Mason Street Advisors LLC increased its position in shares of Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock worth $157,000 after buying an additional 175 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 1,908 shares during the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.